405 related articles for article (PubMed ID: 31689242)
41. EBV-related lymphomas: new approaches to treatment.
Kanakry JA; Ambinder RF
Curr Treat Options Oncol; 2013 Jun; 14(2):224-36. PubMed ID: 23549980
[TBL] [Abstract][Full Text] [Related]
42. Tabelecleucel: First Approval.
Keam SJ
Mol Diagn Ther; 2023 May; 27(3):425-431. PubMed ID: 37016096
[TBL] [Abstract][Full Text] [Related]
43. Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological-immunological monitoring of EBV infection, prompt diagnosis and early treatment.
Chiereghin A; Bertuzzi C; Piccirilli G; Gabrielli L; Squarzoni D; Turello G; Ferioli M; Sessa M; Bonifazi F; Zanoni L; Sabattini E; Lazzarotto T
Transpl Immunol; 2016 Feb; 34():60-4. PubMed ID: 26687013
[TBL] [Abstract][Full Text] [Related]
44. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
Coppoletta S; Tedone E; Galano B; Soracco M; Raiola AM; Lamparelli T; Gualandi F; Bregante S; Ibatici A; di Grazia C; Dominietto A; Varaldo R; Bruno B; Frassoni F; Van Lint MT; Bacigalupo A
Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702
[TBL] [Abstract][Full Text] [Related]
45. Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes.
Lindsay J; Othman J; Heldman MR; Slavin MA
Curr Opin Infect Dis; 2021 Dec; 34(6):635-645. PubMed ID: 34751183
[TBL] [Abstract][Full Text] [Related]
46. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.
Kwong YL; Chan TSY; Tan D; Kim SJ; Poon LM; Mow B; Khong PL; Loong F; Au-Yeung R; Iqbal J; Phipps C; Tse E
Blood; 2017 Apr; 129(17):2437-2442. PubMed ID: 28188133
[TBL] [Abstract][Full Text] [Related]
47. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients.
Barker JN; Martin PL; Coad JE; DeFor T; Trigg ME; Kurtzberg J; Weisdorf DJ; Wagner J
Biol Blood Marrow Transplant; 2001; 7(7):395-9. PubMed ID: 11529490
[TBL] [Abstract][Full Text] [Related]
48. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
Davis JE; Moss DJ
Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
[TBL] [Abstract][Full Text] [Related]
49. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
[TBL] [Abstract][Full Text] [Related]
50. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
[TBL] [Abstract][Full Text] [Related]
51. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
52. Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation.
Jiang X; Xu L; Zhang Y; Huang F; Liu D; Sun J; Song C; Liang X; Fan Z; Zhou H; Dai M; Liu C; Jiang Q; Xu N; Xuan L; Wu M; Huang X; Liu Q
Oncoimmunology; 2016 May; 5(5):e1139274. PubMed ID: 27467959
[TBL] [Abstract][Full Text] [Related]
53. [Clinical Analysis of Treating EBV Infection Accompanied with GVHD after Allon-HSCT by EBV-Specific Cytotoxic T Lymphocytes].
Wang JB; Yuan L; Cheng HY; Fei XH; Gu JY; Xue S; He JB; Zhang WJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1515-1522. PubMed ID: 30295277
[TBL] [Abstract][Full Text] [Related]
54. Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas.
Cohen JI; Bollard CM; Khanna R; Pittaluga S
Leuk Lymphoma; 2008; 49 Suppl 1(Suppl 1):27-34. PubMed ID: 18821430
[TBL] [Abstract][Full Text] [Related]
55. Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation.
Zhou L; Lu DP
Virol J; 2019 Feb; 16(1):19. PubMed ID: 30736814
[TBL] [Abstract][Full Text] [Related]
56. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells.
Moosmann A; Bigalke I; Tischer J; Schirrmann L; Kasten J; Tippmer S; Leeping M; Prevalsek D; Jaeger G; Ledderose G; Mautner J; Hammerschmidt W; Schendel DJ; Kolb HJ
Blood; 2010 Apr; 115(14):2960-70. PubMed ID: 20103780
[TBL] [Abstract][Full Text] [Related]
57. [The efficacy and safety of rituximab in treatment of Epstein-Barr virus disease post allogeneic hematopoietic stem-cell transplantation].
Xu LP; Liu DH; Liu KY; Zhang CL; Wang FR; Wang JZ; Wang Y; Chen H; Zhang YY; Yan CH; Han W; Chen YH; Zhao T; Zhang XH; Huang XJ
Zhonghua Nei Ke Za Zhi; 2012 Dec; 51(12):966-70. PubMed ID: 23327959
[TBL] [Abstract][Full Text] [Related]
58. Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantation.
Pei XY; Liu XF; Zhao XY; Lv M; Mo XD; Chang YJ; Shang QN; Sun YQ; Chen YH; Xu LP; Wang Y; Zhang XH; Liu KY; Huang XJ
Cell Mol Immunol; 2022 Apr; 19(4):482-491. PubMed ID: 35017718
[TBL] [Abstract][Full Text] [Related]
59. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.
Clave E; Agbalika F; Bajzik V; Peffault de Latour R; Trillard M; Rabian C; Scieux C; Devergie A; Socié G; Ribaud P; Adès L; Ferry C; Gluckman E; Charron D; Esperou H; Toubert A; Moins-Teisserenc H
Transplantation; 2004 Jan; 77(1):76-84. PubMed ID: 14724439
[TBL] [Abstract][Full Text] [Related]
60. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.
Leen AM; Christin A; Myers GD; Liu H; Cruz CR; Hanley PJ; Kennedy-Nasser AA; Leung KS; Gee AP; Krance RA; Brenner MK; Heslop HE; Rooney CM; Bollard CM
Blood; 2009 Nov; 114(19):4283-92. PubMed ID: 19700662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
